Ocrevus (Ocrelizumab) Denied by Insurance: Appeal
Ocrevus denied for multiple sclerosis? Learn about MRI requirements, EDSS scores, prior DMT failure, and how to appeal a relapsing or PPMS denial.
Ocrevus (ocrelizumab) is a humanized anti-CD20 monoclonal antibody developed by Genentech (Roche) that depletes B cells involved in the inflammatory process of multiple sclerosis. It is FDA-approved for both relapsing forms of MS (relapsing-remitting MS and active secondary progressive MS) and primary progressive MS (PPMS) — the only approved treatment for PPMS. Despite this unique position and strong clinical evidence, Ocrevus is frequently denied by insurance, often due to complex Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization requirements that reflect the high cost of the drug rather than legitimate clinical doubt about its effectiveness.
What Ocrevus Treats
Ocrevus is given by intravenous infusion twice yearly (after initial split dosing) and is indicated for adults with relapsing MS or PPMS. For relapsing MS, it reduces the rate of relapses and slows disability progression compared to interferon beta-1a. For PPMS — a condition with no other approved disease-modifying therapy — Ocrevus slows disability progression significantly, representing a major advance for a previously untreatable form of the disease.
Why Insurance Denies Ocrevus
MRI requirement is a common PA criterion. Many insurers require recent brain and spinal cord MRI results (often within the past 6–12 months) demonstrating MS lesion activity before approving Ocrevus. If your MRI is not recent, or if the radiologist's report does not use the specific language the insurer is looking for, coverage may be denied.
EDSS score requirements are imposed by some plans that use the Expanded Disability Status Scale to determine eligibility. Plans may deny Ocrevus for PPMS patients whose EDSS score falls outside a specified range, arguing the drug is not appropriate for either very mild or very advanced disability.
Failure of prior DMT is required by many plans before approving Ocrevus for relapsing MS. Insurers often require documented failure of a first-line disease-modifying therapy (such as interferon beta or glatiramer acetate) before approving a high-efficacy agent like Ocrevus. For PPMS patients, this requirement is clinically inappropriate because there are no alternative approved DMTs, but it still appears in some plan documents.
Prior authorization renewal creates recurring access problems. Even patients who were approved initially face re-authorization requirements every 6–12 months, which can disrupt infusion scheduling if re-authorization is delayed.
Site of service restrictions apply because Ocrevus is administered by IV infusion. Some plans require infusions to be performed at specific sites (such as a physician office infusion center rather than a hospital outpatient department), and hospital-based infusions may be denied for cost reasons.
How to Appeal an Ocrevus Denial
Provide recent MRI documentation. If your denial cites a missing or outdated MRI, work with your neurologist to obtain a current scan or to provide the insurer with the most recent report. Make sure the report explicitly describes MS lesion burden and, for relapsing MS, any evidence of disease activity (new or enlarging T2 lesions, gadolinium-enhancing lesions).
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →
Document your EDSS score. Your neurologist should provide a current EDSS assessment as part of the appeal package. If the insurer's policy requires an EDSS in a specific range, have your neurologist document that your score meets this criterion and provide clinical notes supporting the EDSS determination.
Address DMT failure clearly. If you previously tried interferon beta products (Avonex, Rebif, Betaseron) or glatiramer acetate (Copaxone) and they failed, document the treatment period, dose, duration, and reason for failure — whether that was clinical breakthrough disease (new relapses, new MRI activity) or intolerable side effects.
For PPMS patients, emphasize the absence of alternatives. If your insurer is applying a step therapy requirement to a PPMS patient, your neurologist should explicitly state in the medical necessity letter that Ocrevus is the only FDA-approved therapy for PPMS and that step therapy requirements designed for relapsing MS are clinically inapplicable.
Cite clinical trial data. The OPERA I and OPERA II trials demonstrated superior relapse rate reduction and MRI outcomes for Ocrevus vs. interferon beta-1a in relapsing MS. The ORATORIO trial demonstrated slowed disability progression in PPMS. Reference these trials and the NCCN, AAN (American Academy of Neurology), or Consortium of MS Centers guidelines in your appeal.
Request expedited review if infusion is imminent. If your Ocrevus infusion is already scheduled and denial of coverage would cause a gap in treatment, request an expedited appeal citing the clinical risk of delayed B-cell therapy, including potential MS relapses.
Patient Assistance Programs
Genentech offers Genentech Access Solutions, which includes copay assistance and a free drug program for qualifying patients. Visit genentech-access.com or call 1-888-249-4918. A patient navigator can help guide you through both the PA process and assistance program enrollment simultaneously.
Fight Back With ClaimBack
ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.
Fight your denial at ClaimBack →
Related Reading:
How much did your insurer deny?
Enter your denied claim amount to see what you could recover.
Your insurer is counting on you giving up.
Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.
We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.
Free analysis · No credit card · Takes 3 minutes
Related ClaimBack Guides